Anjeanette Damon

Royanne McNair believed she had canceled her contract with a “We Buy Ugly Houses” franchise, so she pursued another offer on her house — this one for $100,000 more. Then an anonymous envelope froze the deal.

ProPublica found few jurisdictions have laws or regulations to protect homeowners from aggressive real estate tactics short of fraud or elder abuse.

Homeowners enrolled in Nevada’s mortgage assistance program have received foreclosure notices when the money fails to make its way from the federal government to the loan providers on time.

While legal, the party’s decision to host a competing contest to the Feb. 6 primary election has angered GOP voters and provided fertile ground for misinformation to take hold, experts say, undermining voters’ trust in the process.

Founded by lobbyists, NZero convinced Nevada government officials, including administrations from two political parties, to pay more and more money despite its struggles to deliver promised real-time carbon emission data.

After recent practice runs showed significant problems in transferring data accurately, the battleground state’s new centralized voter registration system will get its first real-world test in a major presidential election.

National Park Service staff have received talking points ordering them to describe layoffs as “workforce management actions” and to reassure visitors that changes resulting from the cuts won’t impede “memorable and meaningful experiences for all.”

Authorities are investigating why two women fell ill at the Revolution Against Aging and Death Festival. They both received peptide injections, an alternative therapy promoted by Robert F. Kennedy Jr. as a way to fight aging and chronic disease.

Solar power accounts for two-thirds of the new projects waiting to connect to the state’s power grid. Utah Republicans’ hard turn against solar mirrors President Donald Trump’s hostile approach to the industry.

The agency’s 2023 decision to place 19 peptides on the “unsafe” list was supported by numerous documented safety concerns, former officials said. Even though demand for peptide therapies has exploded since then, there’s been little new science.